Ad
ADAP - Adaptimmune Therapeutics plc Stock Trading
About | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Not available
Quote | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
| Last: | $0.799 |
|---|---|
| Change Percent: | -0.13% |
| Open: | $0.8 |
| Close: | $0.80 |
| High: | $0.8 |
| Low: | $0.7652 |
| Volume: | 17,843 |
| Last Trade Date Time: | 09/28/2023 03:00:00 am |
News | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
-
2023-09-12 08:48:00 ET Summary Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for solid tumors. Their afami-cel therapy has demonstrated signs of activity in patients with heavily pretreated sarcoma, with a 2-year rate of overall survival ...
-
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Devel...
Message Board Posts | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
| Subject | By | Source | When |
|---|---|---|---|
| ASCO The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly | jondoeuk | investorshub | 04/30/2023 5:33:59 PM |
| From FB https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evren | jondoeuk | investorshub | 04/14/2023 1:08:05 AM |
| The company said it will regain rights to | jondoeuk | investorshub | 04/11/2023 6:54:34 PM |
| Upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=26880 | jondoeuk | investorshub | 04/10/2023 5:52:14 PM |
| (OT) Two interesting preclinical papers https://jitc.bmj.com/content/11/4/e00551 | jondoeuk | investorshub | 04/05/2023 8:56:43 PM |
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Ad
-
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Devel...
-
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US ma...
-
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded ...